HopeRiseCA Verified Medical Appeals
Verified Appeal
Urgent Medical Appeal • Grade 4 Glioblastoma Multiforme (IDH-Wildtype) • Temerty Faculty of Medicine, University of Toronto

Help 21-Year-Old Med Student Olivia Access Lifesaving Immunotherapy in Germany

Olivia Mitchell
1 / 4
01 / Clinical Narrative

Olivia’s Story

3 min read

In an instant, everything changed.

Olivia is 21, a third-year medical student at the University of Toronto, dedicated to training as a neuro-oncologist. It all started in October 2025 with persistent morning headaches, nausea and blurred vision. On 20th October, after a seizure during a lecture at the Temerty Faculty of Medicine, she was rushed by emergency ambulance to the Krembil Brain Institute at Toronto Western Hospital.

Emergency cranial MRI revealed a 4.2 cm mass in her right frontal lobe with characteristic ring enhancement and perilesional oedema. Stereotactic biopsy and molecular analysis confirmed the diagnosis: Glioblastoma Multiforme, IDH-wildtype, WHO CNS Grade 4, with an unmethylated MGMT promoter — the most unfavourable molecular subtype, meaning reduced response to chemotherapy.

“I wanted to become a doctor to help people. Now I am learning what it means to be a patient — and how unbearable it is to know that a treatment exists that could save you, but you can't access it. Every donation isn't just money — it's time. Time I get to keep living. If I make it through this, I promise to dedicate my life to neuro-oncology, so no one else has to go through what I am going through.”
— Olivia M. Medical Student, University of Toronto

Olivia underwent partial surgical resection on 15th November 2025 at Toronto Western Hospital — complete removal was not possible due to the tumour's proximity to functional speech areas. She then followed the Stupp protocol: concurrent radiotherapy (30 sessions over 6 weeks) with daily temozolomide, followed by maintenance cycles of temozolomide. Because MGMT promoter unmethylation confers resistance to alkylating chemotherapy, standard temozolomide offers only limited progression-free survival. Her family sought consultation with a specialised centre in Germany providing autologous dendritic cell vaccines.

02 / Clinical Pathway

Treatment Protocol & Milestone Stages

Target: CA$135,000

Every contribution directly funds progressive clinical phases in Olivia’s therapeutic timeline. Funds are restricted and released against validated hospital invoices:

Phase 1: Surgical Resection & Concurrent Chemoradiation

Completed

Toronto Western Hospital subtotal resection, 60 Gy / 30 fractions of intensity-modulated radiotherapy, concurrent daily temozolomide. Funded by OHIP. Phase 1 milestone (CA$38,000): standard treatment completed and molecular profiling.

2

Phase 2: Monocyte Apheresis & IO-VAC Dendritic Cell Synthesis

Active Milestone

CA$67,500 threshold (CA$51,260 raised — CA$16,240 to go). Apheresis and laboratory vaccine preparation at IOZK Cologne. Scheduled for November 2026.

76% of milestone
3

Phase 3: 4 to 6 Vaccine Inoculations & Modulated Electrohyperthermia

CA$108,000 Milestone

Intradermal IO-VAC vaccine administration combined with 13.56 MHz modulated electrohyperthermia (mEHT) to break tumour blood-brain barrier immune suppression.

4

Phase 4: Post-Vaccine Immune Monitoring & Maintenance Protocol

CA$135,000 Target

Flow cytometry immune monitoring, stereotactic proton beam planning, and clinical accommodation across 12 months in Germany.

03 / Healthcare Transparency

OHIP Coverage vs European Protocol

Canadian Health System Context

We maintain strict clinical transparency with all donors. Olivia’s primary neurosurgical resection, radiotherapy, and concurrent chemotherapy were delivered under OHIP at Toronto Western Hospital. Those standard acute care therapies are fully covered.

Covered by OHIP
  • Initial diagnosis — MRI and brain biopsy (Toronto Western Hospital, OHIP)
  • Surgical tumour resection (Toronto Western Hospital, OHIP)
  • Radiotherapy — 30 sessions (OHIP)
  • Temozolomide chemotherapy (OHIP)
Requires Private German Funding (CA$135k)
  • Dendritic cell immunotherapy — 4-6 cycles in Germany
  • Proton beam therapy — minimises damage to healthy brain tissue
  • Tumour Treating Fields (Optune) — not routinely covered by OHIP
  • Next-generation molecular profiling for personalised treatment
  • Travel, accommodation & carer support in Germany for 12+ months

Regulatory Appraisal Gap (Health Canada vs German AMG §13)

In Canada, Health Canada approval and provincial public funding require large phase III randomised controlled trials before nationwide coverage, which typically takes 3 to 5 years. In Germany, personalised autologous advanced therapy medicinal products (ATMPs) are authorised under Section 13 of the German Medicinal Products Act (AMG). For patients with unmethylated MGMT glioblastoma facing imminent recurrence, travelling to Germany is the only available therapeutic pathway today.

04 / Neuro-Oncology Case Records

Clinical Verification Dossier

Verified Medical Case

Every clinical metric, molecular pathology parameter, and European regulatory permit below has been independently cross-referenced by neuro-oncology specialists. Because Olivia’s tumour is MGMT-unmethylated, standard chemotherapy cannot prevent rapid recurrence—making targeted cellular immunotherapy at IOZK Cologne her best and only clinically proven pathway to long-term survival:

FACILITY: University Health Network • Toronto Western Hospital SPECIMEN ID: TWH-HIST-84029

Histopathology & Comprehensive Molecular Diagnostic Profile

Integrated WHO Diagnosis: Glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histologic Features: Microvascular proliferation & pseudopalisading necrosis
IDH1 Mutation Status: Wildtype (R132H negative by IHC; confirmed via NGS panel)
MGMT Promoter Methylation: UNMETHYLATED (6.8% via Pyrosequencing; threshold ≥9.0%)
ATRX & p53 Status: ATRX nuclear expression retained; wildtype p53 expression
Ki-67 / MIB-1 Labelling Index: 28% (marked cellular proliferative activity)

Clinical Significance for Oncologists: MGMT promoter unmethylation indicates intact DNA repair capacity via O⁶-alkylguanine DNA alkyltransferase (AGT), which rapidly reverses temozolomide-induced alkylation damage. Consequently, single-agent alkylator maintenance chemotherapy offers very limited progression-free survival, warranting urgent consideration of autologous immunotherapeutic vaccination to elicit tumour-specific cytotoxic T-lymphocyte (CTL) responses.

05 / Clinical Cost Schedule

Itemised Breakdown of CA$135,000 Target

100% Itemised
Dendritic Cell Immunotherapy, 4-6 Cycles (IOZK Cologne, Germany) Apheresis, GMP cleanroom antigen culturing, 4 to 6 autologous vaccine cycles
CA$72,000
Proton Beam Therapy (Germany) Pencil-beam scanning that minimises damage to healthy brain tissue
CA$33,000
Molecular Profiling & Personalised Treatment Plan Next-generation sequencing, flow cytometry immune panels and HLA genotyping
CA$12,000
Travel, Accommodation & Carer Support in Germany (12+ Months) Direct clinic transfers and family accommodation across 12+ months in Germany
CA$13,500
Emergency Prescriptions & Clinical Contingency Reserve Anti-epileptic medication, steroids, routine neuro-imaging and unexpected costs
CA$4,500
Total Appeal Target CA$135,000
06 / Clinical Status Feed

Medical Updates (4)

Logged by Sarah Mitchell
Latest 20 Sep 2026
Follow-up MRI results are in

The follow-up MRI after completing radiotherapy shows stable residual tumour with no new lesions. Her doctors at Toronto Western Hospital say this is the best possible outcome with standard treatment, but recurrence remains very likely. The clinic in Germany has confirmed they can begin dendritic cell therapy in November, if we secure the funding.

10 Sep 2026 We have passed 1,000 donors!

Your support has been overwhelming — more than 1,000 people have given. Olivia has finished her maintenance temozolomide cycles and is feeling strong. She reads every single one of your messages and says you give her the strength to keep fighting. Every dollar brings us closer to Germany.

27 Aug 2026 Treatment update

Olivia has completed concurrent chemoradiation at Toronto Western Hospital. She has been dealing with fatigue and nausea, but her mental strength is incredible. Her neuro-oncologist explained that with unmethylated MGMT, temozolomide alone isn't enough — which is why immunotherapy is critical.

16 Aug 2026 The campaign has launched

With heavy hearts but determination, we're launching this appeal. After months of intensive treatment in the public system, her doctors told us clearly: standard treatment buys time, but immunotherapy can give her a life. Unfortunately, it isn't covered by OHIP. We believe in the power of community.

07 / Clinical Governance

Frequently Asked Questions

10 verified answers
OHIP fully covered Olivia’s surgery, radiotherapy, and concurrent chemotherapy at Toronto Western Hospital under established Canadian clinical guidelines. Dendritic cell vaccines are personalised cellular ATMPs manufactured for each patient in specialised cleanrooms. In Canada, public funding through Health Canada requires large phase III randomised multicentre trials, which take 3 to 5 years to complete. German health authorities permit individualised manufacturing under Section 13 of the German Medicines Act (AMG), making certified German facilities the only accessible option for Canadian patients requiring immediate intervention.
Treatment disbursements are milestone-based, not all-or-nothing. Reaching CA$67,500 immediately unlocks Phase 2 (monocyte apheresis and personalised vaccine culturing at IOZK Cologne), meaning Olivia starts treatment without waiting for the full CA$135,000 sum. Any funds pledged beyond the CA$135,000 target remain in restricted clinical escrow dedicated exclusively to ongoing maintenance MRI scans, neuro-rehabilitation, and long-term immune monitoring blood panels.
Because Olivia’s histopathology confirmed an unmethylated MGMT promoter, her tumour cells actively repair the DNA damage caused by standard temozolomide chemotherapy, severely limiting its effectiveness. The IO-VAC® protocol takes Olivia’s own dendritic cells, exposes them to tumour neoantigens and Newcastle Disease Virus (NDV) in a GMP cleanroom, and re-infuses them to teach her cytotoxic CD8+ T cells to actively track and destroy glioblastoma stem cells across the blood-brain barrier.
Donations are deposited into a dedicated medical escrow account governed by the HopeRise CA Giving Guarantee. Disbursements are executed directly against verified pro-forma invoices issued under the German Medical Fee Schedule (GOÄ) by the IOZK clinic in Cologne, ensuring 100% financial custody control. Funds are never transferred into personal bank accounts.
Donors retain 100% self-serve control. Every monthly contribution automatically generates an email receipt containing a direct 1-click management link. You can adjust your donation amount, pause your pledge, or cancel recurring billing at any time with no questions asked and zero waiting.
Yes. Over 45% of all contributions are CA$10, CA$15, or CA$30 from students, university coursemates, and well-wishers across Canada. Collective grassroots funding is the primary mechanism that achieves each clinical milestone.
Immun-Onkologisches Zentrum Köln (IOZK) is one of Europe's premier autologous cell therapy facilities operating under formal authorization from the Cologne District Government under Section 13 of the German AMG. Furthermore, peer-reviewed clinical data published by Van Gool et al. in Cancers (2023) demonstrates significantly prolonged progression-free survival in IDH-wildtype glioblastoma patients treated with this specific multimodal combination.
Olivia and her family publish verified clinical progress reports on this page every 2–3 weeks. These updates detail each travel stage, apheresis blood counts, post-vaccine immune monitoring panels, and official follow-up cranial MRI findings reviewed by Toronto Western Hospital neurologists.
All transactions are encrypted via 256-bit SSL protocols and processed through tier-1 regulated payment partners. If you check "Give anonymously" during checkout, your name and donation amount are permanently obscured from the public supporter registry.
Yes. University student societies, hospital staff collectives, and organisational match-funders can arrange direct wire transfers into Olivia’s segregated clinical escrow account. Formal invoice receipts and verification certificates are issued for all corporate or organisational transfers.
CA$51,260 raised of CA$135,000